3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
KOYN, a SPAC, entered a business combination agreement with First Digital Group, the developer of the FDUSD stablecoin and Finance District, valuing First Digital at $250 million on a pre-money equity basis. Closing is expected in the first half of 2027 and requires approval by shareholders of both companies and regulatory approvals, so KOYN shareholders face deal execution risk.
Business combination agreement signed October 6, 2026; First Digital valued at $250 million pre-money equity, with no minimum cash condition
First Digital reported approximately $87 million in revenue for the fiscal year ended June 30, 2025
Closing expected in the first half of 2027, subject to shareholder, regulatory and Form F-4 effectiveness conditions
Non-binding term sheet with Millennial Trading Limited for a $25 million convertible note at a $12.00 conversion price; no assurance it will be finalized
On September 30, 2026, four Greenlane subsidiaries assigned substantially all their assets to Philip J. von Kahle, who will liquidate them and distribute proceeds to creditors under Florida law. The company will deconsolidate these entities as of September 30, 2026, and says it received no consideration, while the assignments do not release the subsidiaries from their liabilities and claims may be asserted against the company. The entities conducted the company's legacy wholesale distribution business, which had been substantially wound down before the assignments.
Four subsidiaries, including Greenlane Holdings, LLC, executed assignments for the benefit of creditors on September 30, 2026, to assignee Philip J. von Kahle.
Preliminary gain on deconsolidation of approximately $3.2 million, based on June 30, 2026 balances; the final figure will appear in the 10-Q for the quarter ended September 30, 2026.
The company received no consideration; a $60,000 retainer was paid from Warehouse Goods LLC, and the company agreed in principle to lend the assignee $100,000, though no loan agreement has been signed.
Unaudited pro forma 2025 net loss of $48.1 million, compared with a historical net loss of $85.6 million, excluding the deconsolidated entities.
Ocean Power Technologies said Chief Financial Officer Robert Powers left the role on September 30, 2026, by mutual agreement with the Board. Victoria Hay, co-owner and President of consulting firm Flexible Consulting, is serving as interim CFO, Principal Financial Officer and Principal Accounting Officer under an engagement agreement, and the Board is searching for a permanent CFO. The change affects who leads the company's finance function until a permanent CFO is named.
Robert Powers departed as CFO effective September 30, 2026, upon mutual agreement with the Board, and remains employed through October 14, 2026 to assist with the transition.
Victoria Hay, 43, began serving as interim CFO effective September 30, 2026, through an engagement agreement with Flexible Consulting.
Flexible Consulting will receive $30,000 per month for Hay's services, plus monthly expense reimbursement.
Powers will receive six months of base salary, the balance of his fiscal 2026 bonus, and health benefits through October 31, 2026.
QuasarEdge Acquisition Corp (QRED) entered into a First Amendment to its June 9, 2026 Agreement and Plan of Merger with Robseek parties on October 6, 2026. The amendment changes the share structure of the purchaser to a single class of ordinary shares, sets 100,000,000 aggregate closing payment shares, and revises lock-up terms for shares issued to QRED shareholders. These changes alter the terms shareholders would receive if the merger closes.
Amendment dated October 6, 2026 amends the Merger Agreement signed June 9, 2026
Aggregate of 100,000,000 closing payment shares under the amended shareholder allocation schedule
Each QRED right entitles holder to one-fourth of one Purchaser ordinary share upon initial business combination
Lock-up lasts until the earlier of 180 days after closing or a $12.50 trading-price condition beginning at least 90 days after closing
Chevron agreed to transfer its ownership interests and general partner position in Hess Midstream LP, plus its DJ Basin crude oil midstream assets, in exchange for extended Bakken midstream contracts, new DJ Basin contracts and $200 million in cash. Chevron expects a one-time after-tax loss of approximately $3 to $4 billion at closing, which it expects to treat as a special item, and expects the deal to close by year-end 2026.
At closing, Chevron expects a one-time after-tax loss of approximately $3 to $4 billion, treated as a special item.
Chevron expects to reduce its Bakken unit midstream costs by approximately 50% and to increase return on capital employed.
Chevron receives $200 million in cash and expects to fully deconsolidate Hess Midstream, including about $3.7 billion of its debt.
The deal is expected to close by year-end 2026, subject to customary closing conditions and regulatory approvals.
Rocket Pharmaceuticals entered a Loan and Security Agreement with Hercules Capital on September 30, 2026, providing up to $150.0 million in senior secured term loans, with $35.0 million funded at closing. The company also issued warrants to the lenders for 1,755,853 shares of common stock at $2.99 per share, which adds potential dilution, and the loans are secured by substantially all of the company's assets.
Tranche 1-A advance of $35.0 million funded September 30, 2026; further tranches total up to $115.0 million at the company's option or the lenders' approval
Loans mature October 1, 2030, with interest at the greater of prime or 6.75%, plus 2.40%
Warrants for 1,755,853 shares at $2.99 per share; 409,699 shares exercisable after the Tranche 1-A funding
Prepayment charges of 3.00%, 2.00% or 1.00% depending on timing; minimum cash covenant not tested while market capitalization exceeds $600.0 million
Fair Isaac committed on October 1, 2026 to a workforce reduction that eliminates about 15% of its positions, while reducing management layers, simplifying its operating structure, and integrating AI-driven product development. The company expects aggregate pre-tax charges of about $27.0 million in the fourth quarter of fiscal 2026, mostly severance, and the plan is expected to be substantially complete by the end of the third quarter of fiscal 2027.
About 15% of positions across the company will be eliminated.
Expected pre-tax charges of approximately $27.0 million in Q4 fiscal 2026, mainly employee severance and related costs.
Affected employees began being notified the week of October 5, 2026.
Plan expected to be substantially completed by the end of Q3 fiscal 2027.
At a special meeting on October 6, 2026, stockholders approved raising authorized common stock from 250,000,000 to 275,000,000 shares and approved issuing common stock on conversion of Series C preferred stock and warrants, which the filing says could exceed 20% of outstanding shares and may, with management and board changes, result in a change of control. The filing body names Quince Therapeutics, Inc. while the header lists IRulya Therapeutics Inc., so the registrant identity should be confirmed. For shareholders, the approvals add capacity for potential dilution and a possible change in control.
Authorized common stock increased from 250,000,000 to 275,000,000 shares, effective October 6, 2026
Proposal 2 passed with 343,517 votes for and 5,759 against; Proposal 1 passed with 180,550 votes for and 5,742 against
Proposal 1 may result in a change of control under Nasdaq Listing Rule 5635(b)
2026 Equity Incentive Plan reserve starts at 821,872 shares; 2026 ESPP reserve starts at 142,045 shares
Curtiss-Wright said CFO K. Christopher Farkas will retire effective at calendar year-end 2026 and will remain Executive Vice President until then. The Board appointed Senior Vice President and Corporate Controller Gary A. Ogilby as interim CFO effective October 6, 2026, while it searches for a permanent successor. The company states the retirement is unrelated to its business or financial performance.
Farkas stepped down as CFO and will stay as Executive Vice President until his retirement date at calendar year-end 2026
Ogilby, 45, joined the company in 2010 and has been Corporate Controller since May 2020; he keeps that role while serving as interim CFO
Compensation for Ogilby's interim CFO role has not been determined as of the filing date
The company reports third-quarter earnings on November 4, 2026
On October 6, 2026, Sysco Corporation and Sysco Holdings Corporation issued $10.75 billion of USD senior notes, $3.9 billion of USD junior subordinated notes and €1.0 billion of euro junior subordinated notes. The issuers plan to use the net proceeds to pay part of the cash consideration for the pending acquisition of JRD Unico, Inc. and Warehouse Realty, LLC, or, if that acquisition is not completed, to fund a special mandatory redemption of the notes other than the 2036 senior notes. The filing adds a large amount of new debt, with maturities running from 2029 to 2066.
USD senior notes totaling $10.75 billion across seven series maturing 2029 to 2066, with coupons from 5.450% to 6.600%
USD junior subordinated notes totaling $3.9 billion in three series due October 6, 2056, with coupons from 7.100% to 7.350%
Euro junior subordinated notes of €1.0 billion at 6.000%, due 2056
Proceeds are earmarked for the pending acquisition of JRD Unico, Inc. and Warehouse Realty, LLC
Penguin Solutions appointed Stephen Cumming as Senior Vice President and Chief Financial Officer, effective October 6, 2026. He replaces Aaron Johnson, who had been interim CFO since July 9, 2026 and returns to his prior role as Vice President, Finance and Accounting. The filing also discloses Cumming's pay package, including a $700,000 retention bonus and equity grants totaling $4.3 million in target value, which matter to shareholders as a cost and as a sign of who leads the company's finances.
Stephen Cumming, formerly CFO of Edgio, Inc. (2022 to 2025), starts as SVP and CFO on October 6, 2026, succeeding interim CFO Aaron Johnson.
Base salary of $550,000, with an annual bonus targeted at 90% of base salary, prorated for fiscal 2027.
$700,000 retention bonus payable in two equal installments within 45 and 85 days of his start date.
Equity grants of $1,750,000 in time-based RSUs and $2,550,000 in relative TSR-based PSUs (0% to 200% of target).
Powerus Corporation completed its merger with Autonomous Power Corporation on October 1, 2026, issuing approximately 134.6 million shares of common stock. The company also named Colin Chisholm as Chief Operating Officer, with a start date of October 12, 2026, and an employment agreement with a $325,000 base salary and a grant of 300,000 restricted stock units.
Merger with Autonomous Power Corporation closed on October 1, 2026, with about 134.6 million shares issued
Shares outstanding immediately after the merger closing: 163,838,861
Colin Chisholm appointed COO on October 1, 2026, expected to start October 12, 2026
Chisholm's agreement: two-year initial term, $325,000 base salary, target annual incentive of 30-40% of base salary, and 300,000 RSUs vesting in six-month increments over four years
BeyondSpring completed the sale of BeyondSpring Ltd., which indirectly holds its interest in Bulin, to Biolin Investment Limited on September 30, 2026. The Company received no cash; the buyer's consideration is a commitment to fund the China portion of the DUBLIN-4 Phase 3 trial and a license to the resulting data. The Company no longer controls the disposed entities or SEED Therapeutics, and the pro forma figures show a preliminary gain of $53.7 million that is not yet final.
No cash consideration was paid or payable at closing on September 30, 2026
Non-cash consideration: the Investor's obligation to fund and complete the China portion of DUBLIN-4, plus a license to the trial data
Preliminary pro forma gain on disposition of $53.7 million (about $53,677 thousand); excludes contingent consideration and may differ materially
After the sale, the Company retained about 29% of SEED's voting power on an as-converted basis but no control of SEED
Virtuix Holdings Inc. (VTIX) received a Nasdaq notice on September 30, 2026, saying its market value of listed securities fell below the $50 million minimum for the Nasdaq Global Market. The company has until March 29, 2027 to regain compliance, and its shares continue to trade under VTIX for now. If it fails to meet the requirement, Nasdaq could begin delisting proceedings, which would put the stock's listing at risk.
Nasdaq notice dated September 30, 2026, based on market value of listed securities from August 18 to September 29, 2026
Minimum market value requirement is $50 million for continued listing on the Nasdaq Global Market
Compliance period runs until March 29, 2027, requiring at least ten consecutive business days at or above $50 million
Company also does not meet the alternative total assets and total revenue standard; it may apply to transfer to the Nasdaq Capital Market
Clarivate completed the sale of its Life Sciences & Healthcare segment to an affiliate of Altaris, LLC on October 6, 2026, for a total value of $600 million, according to the company's press release. The company says it will use the proceeds to reduce debt, and it will update its full year 2026 guidance to reflect the divestiture when it reports third quarter results on November 3, 2026.
Cash paid at closing was $500 million, subject to customary adjustments, plus a $75 million unsecured senior note issued by an Altaris affiliate.
A further $25 million of deferred consideration is payable later, no earlier than the conditions tied to transition services and no later than January 31, 2028.
Henry Levy, President of Life Sciences & Healthcare, left his subsidiary role at closing under a separation agreement tied to a retention agreement.
Clarivate will file pro forma financial statements by October 13, 2026, and report third quarter 2026 results on November 3, 2026.
Penguin Solutions reported fourth-quarter fiscal 2026 net sales of $567 million, up 68% year over year, and GAAP diluted EPS of $1.29 versus $0.11 a year earlier. The company raised its fiscal 2027 outlook, now expecting net sales of about $2.43 billion at the midpoint, growth of about 40%, which it attributes to AI Infrastructure demand.
Q4 fiscal 2026: net sales $567 million, up 68%; GAAP diluted EPS $1.29 vs. $0.11; non-GAAP diluted EPS $1.00 vs. $0.43
Full fiscal 2026: net sales $1.73 billion, up 26%; net income attributable to Penguin Solutions $181 million
Fiscal 2027 outlook: net sales about $2.43 billion at midpoint (about 40% growth); GAAP diluted EPS $3.50; non-GAAP diluted EPS $4.45
BioMarin said its third-quarter 2026 results will include about $283 million of acquired in-process R&D expense tied to its Alesta Therapeutics acquisition, completed August 31, 2026. The company estimates the charges reduce both GAAP and non-GAAP diluted EPS by about $1.50 for the quarter and about $1.55 for the full year, and it will update full-year 2026 guidance with its third-quarter results.
Q3 2026 pre-tax IPR&D charge of approximately $283 million, an unfavorable EPS impact of about $1.50
Full-year 2026 pre-tax charges of approximately $320 million, an unfavorable EPS impact of about $1.55
Prior full-year 2026 guidance, announced August 6, 2026, did not reflect the Alesta acquisition
Quarter results are not finalized and figures are preliminary and unaudited
Constellation Brands reported fiscal second-quarter 2027 net sales up 6% to $2,633 million and reported EPS up 25% to $3.32, though reported operating income fell 8% to $805 million. The company raised its fiscal 2027 reported EPS outlook to $11.85-$12.55 and reaffirmed its comparable EPS outlook of $11.20-$11.90, and it also announced the completed SpikedAde acquisition and a $1.03 quarterly dividend.
Net sales rose 6% to $2,633 million; reported operating income fell 8% to $805 million, and reported operating margin was 30.6% versus 35.2% a year earlier.
Reported EPS was $3.32, up 25%; comparable EPS was $3.74, up 3%.
Fiscal 2027 reported EPS outlook updated to $11.85-$12.55; comparable EPS outlook reaffirmed at $11.20-$11.90.
Quarterly dividend of $1.03 per Class A share is payable November 13, 2026, to holders of record on October 30, 2026; SpikedAde acquisition included a $75 million payment at close and up to $278 million of contingent consideration over five
Rocky Mountain Chocolate Factory agreed to sell its Durango, Colorado property, which serves as its corporate headquarters and production and warehouse facility, to American Heritage Legacies, LLC for $6.6 million, and will lease it back for 10 years. The buyer is controlled by the family of Interim CEO Allen Harper, making the deal a related party transaction, and proceeds will repay $6.6 million of notes at 12% annual interest held by entities affiliated with board members Steven L. Craig and Jeffrey R. Geygan, which reduces debt but commits the company to rent and a possible buyback obligation if control changes.
Sale price is $6.6 million; closing is expected on or about October 15, 2026, with an independent appraisal supporting the price
Net proceeds are expected to repay $6.6 million of notes accruing 12% per annum, held by RMC Credit Facility LLC and RMCF2 Credit, LLC
Lease has a 10-year initial term, first-year annual rent of $624,000 rising 2% a year, and an option to renew for 10 more years
On a change of control, the lease terminates and, at the landlord's option, the company must buy back the property for the greater of $6.93 million or appraised value
Navitas Semiconductor completed its acquisition of Claros, Inc., a developer of integrated voltage regulator technology for AI data center power delivery, on October 6, 2026, under a merger agreement dated August 24, 2026. The company said the deal raises its identified 2030 serviceable addressable market to over $8 billion, with Claros adding at least $3.5 billion. The filing does not disclose the purchase price or any financial results for Claros.
Closing took place October 6, 2026, under the Merger Agreement dated August 24, 2026.
Claros develops integrated voltage regulator (IVR) technology for power delivery to AI processors.
Navitas expects Claros to add at least $3.5 billion to its 2030 serviceable addressable market, bringing the total to over $8 billion.
A webinar on Claros technology is scheduled for October 20, 2026, at 8:00 a.m. Pacific Time.
Byline Bancorp entered a definitive merger agreement to acquire Illinois State Bancorp, a Chicago-area bank holding company with total assets of approximately $617.3 million as of June 30, 2026. The deal is valued at about $87.9 million based on Byline's October 5, 2026 closing price, and it requires Illinois State Bancorp shareholder approval and regulatory approvals, with closing expected in the first quarter of 2027.
Consideration: about 1.4 million Byline shares, $28.9 million in cash to Illinois State Bancorp shareholders, and about $5.1 million in cash to settle stock options
Value of $261.23 per Illinois State Bancorp common share, based on Byline's $37.63 closing price on October 5, 2026
Byline expects minimal tangible book value dilution of 1.2% and earnback in less than 1.5 years, with mid-single digit EPS accretion
Merger costs are expected to be about $16.6 million pre-tax; closing is anticipated in 1Q27
Millrose Properties completed a $1.0 billion offering of senior notes in two equal tranches, $500.0 million due 2029 at 6.500% and $500.0 million due 2031 at 6.750%. The company takes on new long-term debt, and the 2031 notes must be redeemed at par if the Dream Finders Transaction with Beazer Homes is not completed by May 13, 2027.
Two tranches of $500.0 million each: 6.500% senior notes due October 15, 2029 and 6.750% senior notes due October 15, 2031
Interest is payable April 15 and October 15 each year, starting April 15, 2027
2031 notes must be redeemed at 100% of principal plus accrued interest if the Dream Finders and Beazer Homes merger is not completed by May 13, 2027 or is terminated
Notes are unsecured and rank equally with existing senior debt, including the 6.375% notes due 2030 and 6.250% notes due 2032; the notes are effectively subordinated to secured debt
Caribou Biosciences' Board approved a restructuring on October 2, 2026 that includes discontinuing clinical trials and development of its vispa-cel and CB-011 allogeneic CAR-T programs, a substantial workforce reduction, and a review of strategic alternatives, including a possible merger or acquisition. The company expects restructuring expenses of $15 million to $19 million, and its CFO's employment will end when it signs a binding agreement for a strategic alternative, which shareholders should weigh against the company's remaining cash of $113.8 million as of June 30, 2026.
Estimated total restructuring expenses of $15 million to $19 million, with a substantial portion expected in the fourth quarter of 2026; charges for lease, contract and asset impairments are not yet estimated.
Clinical development ends for vispa-cel and CB-011; the majority of affected employees are expected to depart in the fourth quarter of 2026.
CFO Sriram Ryali's employment will terminate when the company executes a binding definitive agreement for a strategic alternative, treated as a termination without cause.
Wedbush Securities Inc. is the exclusive financial advisor; the company has not set a timeline for the review.
Nasdaq's Listing Qualifications Staff determined to delist Kyntra Bio's common stock after the company did not show compliance with Listing Rule 5450(b) by the September 29, 2026 deadline. Kyntra Bio has requested a hearing before a Nasdaq Hearings Panel, and the stock will keep trading under KYNB while the Panel decides, so shareholders face continued uncertainty over the listing.
Staff determination letter dated September 30, 2026; compliance deadline was September 29, 2026
Company timely requested a Nasdaq Hearings Panel review, which stays the suspension and delisting
Extension period could be up to 180 days from the Staff determination under Listing Rule 5815(c)(1)(A)
Company previously received a April 2, 2026 notice on total assets, total revenue and stockholders' equity or market value standards; no assurance the Panel will grant continued listing
Neighborhood Intelligence sold about 10.9 million common shares plus pre-funded and common warrants in a registered direct offering that closed October 6, 2026, with approximately $42.6 million in net proceeds. The company also cut its at-the-market program ceiling from $200 million to $75 million, and its Executive Chairman and CEO bought shares at the same $2.76 price, so the offering adds share count and potential dilution for existing holders.
Offering of 10,881,192 common shares at $2.76 per share, plus pre-funded warrants for 5,241,997 shares and common warrants for 16,123,189 shares, closed October 6, 2026.
Net proceeds of approximately $42.6 million, which the company intends to use to accelerate merger synergies and build inventory.
Maximum aggregate offering price under the at-the-market program reduced from $200,000,000 to $75,000,000 on October 5, 2026.
Company and directors and executive officers agreed to lock-ups of 90 days after closing; Marcus Lemonis bought 362,319 shares at $2.76.
Neogen reported first-quarter fiscal 2027 revenue of $222.8 million, up 6.5% from a year earlier, and raised its fiscal 2027 revenue and Adjusted EBITDA guidance. The company still posted a GAAP net loss of $11.9 million, compared with net income of $36.3 million a year earlier, when a $76.4 million gain on the sale of a business boosted results.
Revenue of $222.8 million vs. $209.2 million a year earlier; core revenue growth of 8.1%
Net loss of $11.9 million, or $(0.05) per diluted share, vs. net income of $36.3 million, or $0.17, a year earlier; Adjusted EPS was $0.08 vs. $0.04
Fiscal 2027 revenue guidance raised to $885 million to $890 million from $880 million to $885 million; Adjusted EBITDA guidance raised to $181 million to $183 million from $180 million to $182 million
Pending sale of the Genomics business to Zoetis Inc. is expected to conclude regulatory reviews by the end of December 2026
IES Holdings closed its acquisition of DBM Global, a structural steel fabrication and construction services company, for total consideration of approximately $691 million in cash and stock. The company also amended its credit agreement to increase borrowing capacity to $700 million, and it funded the cash portion partly with $525 million of borrowings. The filing does not give DBM Global's earnings, so shareholders cannot yet assess the deal's effect on profit.
Total consideration of approximately $691 million: about $545 million in cash and 430,974 shares valued at about $146 million
Credit facility increased to $700 million, including a $200 million term loan and $500 million revolving credit facility
DBM Global generated revenue of approximately $1.5 billion for the twelve months ended June 30, 2026, and has about 4,000 employees
Financial statements and pro forma information for the acquisition will be filed by amendment later
Apogee Enterprises reported fiscal second-quarter 2027 net sales up 9.2% to $391.1 million and adjusted diluted EPS of $1.17, up from $0.98. GAAP diluted EPS fell 2.7% to $1.07 and net earnings fell 5.4%. The company raised its fiscal 2027 adjusted diluted EPS guidance to $3.00-$3.40 from $2.70-$3.25, which matters to shareholders because it reflects higher expected earnings, though GAAP profit declined in the quarter.
Q2 net sales rose 9.2% to $391.1 million, including a $16.4 million contribution from the Kalwall acquisition
Q2 GAAP diluted EPS was $1.07 versus $1.10; net earnings were $22.4 million versus $23.6 million
Q2 adjusted diluted EPS was $1.17 versus $0.98, a 19.4% increase
Fiscal 2027 net sales guidance raised to $1.46 billion-$1.50 billion from $1.38 billion-$1.43 billion
Repligen said on October 6, 2026 that it completed its acquisition of BioLife Solutions, under a merger agreement dated July 21, 2026. BioLife shareholders received $11.25 in cash and 0.1442 Repligen common shares for each BioLife share, and BioLife's stock is set to stop trading and be removed from Nasdaq. Repligen has not yet quantified the deal's expected effect on its 2026 outlook and plans to address it on its third quarter 2026 earnings call.
Each BioLife share converted into 0.1442 Repligen common shares plus $11.25 in cash, per the filing.
The Mergers closed on October 6, 2026; BioLife notified Nasdaq of the closing that day.
BioLife common stock was to be halted after the after-market session on October 5, 2026, and suspended as of the close on October 6, 2026.
Repligen will provide details on the transaction's expected impact on its 2026 outlook on its third quarter 2026 earnings call.
BioLife Solutions became a wholly owned subsidiary of Repligen after the two companies closed their merger on October 6, 2026. Each BioLife share was converted into 0.1442 Repligen shares plus $11.25 in cash, and BioLife stock is set to be suspended from Nasdaq and deregistered, so shareholders no longer hold a public BioLife stake.
Each BioLife share converted into 0.1442 Repligen common shares plus $11.25 in cash, without interest.
Mergers closed on October 6, 2026; BioLife stock to be suspended from Nasdaq at the close of business that day.
Stockholders adopted the merger agreement at the October 5, 2026 special meeting: 40,910,337 for, 83,451 against, 807 abstaining.
All BioLife directors and five named executive officers resigned effective at the First Merger Effective Time.
Skydance Corporation, formerly Paramount Skydance, completed its acquisition of Warner Bros. Discovery on October 6, 2026, and began trading as SKYD on the NYSE under the new name. The company issued $41.4 billion of senior secured notes on October 5 to help finance the deal, and the filing estimates total cash consideration to WBD shareholders at $78.0 billion, so the transaction adds substantial debt and share issuance for existing shareholders.
WBD shareholders receive $31.00 per share in cash plus ticking consideration; the press release cites $31.01666668 per share
Company issued $41.4 billion of senior secured notes on October 5, 2026, including $30.0 billion first lien and $11.4 billion second lien dollar notes plus €885 million euro notes
Equity investors bought about 3,918 million new Class B shares at $12.00 per share
Management targets at least $6 billion in run-rate synergies within three years and net leverage of 3.0x by the end of 2029
Clean Energy Fuels said Robert Vreeland is departing as Chief Financial Officer and named Jason J. Armstrong, its former Vice President and Corporate Controller, as CFO effective October 6, 2026. Armstrong will also serve as principal financial and principal accounting officer, and the company says Vreeland is expected to retire. The change places a long-time internal finance executive in the top finance role, and the filing lists his pay, equity grant and severance terms.
Jason J. Armstrong, Vice President and Corporate Controller since 2015, succeeds Robert M. Vreeland as CFO effective October 6, 2026.
Armstrong's employment agreement runs to October 6, 2029, with a $500,000 base salary and an annual bonus of up to 100% of salary.
Armstrong received an incremental grant of 35,000 time-vesting restricted stock units, vesting in three annual installments.
Vreeland is expected to sign a release and receive accelerated equity vesting and qualifying termination benefits under his prior employment agreement.
On October 2, 2026, TPG RE Finance Trust closed the TRTX 2026-FL8 collateralized loan obligation through wholly owned subsidiaries, issuing floating rate notes due 2044 with a $600 million Class A tranche, plus preferred shares. The company said proceeds were used to buy three whole loans and 17 participation interests, and to repay pre-closing warehouse and other financing. For shareholders, the filing describes new long-term secured financing for the loan portfolio, but it does not report earnings or guidance.
Closed October 2, 2026; the $600 million Class A notes were rated AAAsf by Fitch, with an expected weighted average life of 3.12 years
Collateral of three whole loans and 17 participations had an aggregate principal balance of about $1.0 billion as of September 9, 2026, roughly 23.1% of the loan portfolio as of June 30, 2026
Proceeds repaid amounts owed for pre-closing financing, including warehouse lines secured by certain of the collateral interests
Company subsidiaries retained the Class D and E notes, acquired the Class F and G notes, and the FL8 Retention Holder acquired 68,750 preferred shares with a $1,000 liquidation preference per share
Auddia cancelled its special stockholder meeting, which had been adjourned to October 7, 2026, to vote on the merger with Thramann Holdings. Based on proxies and ballots received, there were not enough votes to approve the merger, because Delaware law requires a majority of outstanding shares entitled to vote, and about 89% of votes cast were in favor. The company expects to reschedule the meeting with a new record date after further announcements.
About 89% of votes cast on the merger were in favor, but favorable votes fell short of the majority of outstanding common shares required under Delaware law.
The meeting originally scheduled for September 23, 2026 was adjourned to October 7, 2026, and was cancelled on October 6, 2026.
The company expects to set a new record date and reschedule the vote, and will issue a CEO letter to shareholders later this week.
The merger agreement is dated February 17, 2026 and would form McCarthy Finney Inc., expected to trade as MCFN.
Option Care Health entered into a merger agreement on October 5, 2026, under which an investor group of CD&R affiliates and McKesson Corporation would acquire the company for $32.05 per share in cash, a total enterprise value of approximately $5.8 billion. The price represents a premium of approximately 37% to the October 5, 2026 closing share price, and the company's board unanimously recommended the deal to stockholders. Shareholders would receive cash and the stock would no longer be publicly listed on Nasdaq once the deal closes, which is expected in the first half of 2027, subject to stockholder and regulatory approvals.
Cash consideration of $32.05 per share, a premium of approximately 37% to the October 5, 2026 closing price
Total enterprise value of approximately $5.8 billion; McKesson to invest approximately $1.4 billion for an approximately 49% minority interest
Closing expected in the first half of calendar year 2027, subject to stockholder approval and regulatory approvals
Company is withdrawing its previously disclosed 2026 guidance and will not host a call for its third quarter 2026 results, which it expects to release on November 4, 2026
HubSpot's board authorized a restructuring plan on October 1, 2026 that eliminates certain roles, affecting about 7% of the workforce; the CEO's employee memo says nearly 660 people will leave. The company estimates $65 million to $75 million in charges, mostly recognized in the fourth quarter of fiscal 2026, and will exclude them from non-GAAP results, while reaffirming its third-quarter and full-year 2026 revenue, non-GAAP operating income and non-GAAP EPS guidance.
Board authorized the plan on October 1, 2026; it affects about 7% of the workforce, and the CEO's memo cites nearly 660 employees.
Estimated charges of $65 million to $75 million, mainly severance, notice period, employee transition and benefits payments.
Majority of charges expected in fourth quarter 2026; role eliminations substantially complete by end of first quarter 2027; substantially all cash payments by June 30, 2027.
Company reaffirmed third-quarter 2026 and fiscal 2026 revenue, non-GAAP operating income and non-GAAP EPS guidance.
Stryker said CEO Kevin Lobo will step down on December 31, 2026, and become Executive Chair of the Board on January 1, 2027. President and COO Spencer Stiles will become CEO on the same date and join the Board, which the company is expanding from 10 to 11 members. The filing describes this as a planned succession process and does not report any change to financial results or guidance.
Kevin Lobo resigns as CEO on December 31, 2026, and becomes Executive Chair effective January 1, 2027
Spencer Stiles, President and COO since January 2026, becomes CEO and a Board member effective January 1, 2027
Stiles's base salary rises to $1,320,000 and his annual bonus target to 150% of salary; a February 2027 equity award with a target grant value of $14,200,000 will be recommended to independent directors
Lobo's base salary, bonus target and benefit eligibility are unchanged, but he will not receive new stock awards as Executive Chair
McKesson and CD&R agreed to acquire Option Care Health for $32.05 per share, a total enterprise value of approximately $5.8 billion. McKesson will invest approximately $1.4 billion for a minority stake of approximately 49%, while CD&R will hold approximately 51%, and the filing describes a framework for McKesson to later acquire CD&R's interest.
Price of $32.05 per share, a premium of approximately 37% to Option Care Health's October 5, 2026 closing price
McKesson to invest approximately $1.4 billion for a minority stake of approximately 49%; CD&R to hold approximately 51%
Expected to close in the first half of calendar 2027, subject to Option Care Health stockholder approval and regulatory approvals
Lamb Weston reported fiscal first-quarter 2027 net sales up 1% to $1.67 billion, but reported net income fell 55% to $29 million and diluted EPS fell to $0.21 from $0.46. The company raised its full-year fiscal 2027 adjusted diluted EPS outlook to $3.05 to $3.35 from $2.95 to $3.25, and its adjusted EBITDA outlook to $1.125 billion to $1.215 billion from $1.10 billion to $1.20 billion.
Q1 net sales rose 1% to $1.67 billion; North America sales rose 5% while International sales fell 8%.
Reported diluted EPS was $0.21 versus $0.46 a year earlier; adjusted diluted EPS was $0.75 versus $0.74.
Adjusted EBITDA was $286 million, down 5%; International segment Adjusted EBITDA fell 54% to $27 million.
Fiscal 2027 adjusted diluted EPS outlook raised to $3.05 to $3.35; the company did not repurchase shares in the quarter and $245 million remains authorized for buybacks.
On September 30, 2026, subsidiary Boost Run LLC entered a Service Agreement with Cohere Inc to provide dedicated GPU cloud computing infrastructure. Cohere has committed to pay approximately $525.6 million over the term, part of it as a prepayment, subject to delivery and acceptance. Payments depend on infrastructure delivery, and Cohere can terminate and receive refunds of prepaid amounts in certain cases, including if a minimum amount is not accepted by July 15, 2027.
Cohere has committed to pay approximately $525.6 million over the Agreement term, subject to delivery and acceptance requirements.
Each rack has a term of approximately five years from Cohere's acceptance; acceptance of the initial infrastructure is expected to begin in the second quarter of 2027.
If a specified minimum amount of infrastructure is not accepted by July 15, 2027, Cohere may terminate and receive a refund of all prepaid amounts.
Boost Run Inc. has guaranteed refunds of prepaid amounts, up to the prepayment received and not applied against fees.
OFS Capital Corporation's subsidiary OFS SBIC I, LP admitted a third-party investor as a limited partner on October 5, 2026, and the investor acquired 56.62% of the partnership's interests for $52,279,500. The filing says the full payment was distributed to OFS Capital, which plans to use the net proceeds to fund investments and for general corporate purposes. The partnership holds Pfanstiehl Holdings shares that represented about 84.0% of OFS Capital's net assets as of June 30, 2026, and the general partner keeps sole control of the partnership.
Transaction closed October 5, 2026; New Investor acquired 56.62% of SBIC I LP limited partnership interests
New Investor paid $52,279,500, all of which was distributed to OFS Capital Corporation
SBIC I LP holds 400 Class A shares of Pfanstiehl Holdings, about 84.0% of net assets and 31.8% of total investments at fair value as of June 30, 2026
OFS SBIC I GP, LLC, a wholly owned subsidiary, remains general partner with sole control
Regeneron and Sanofi amended their antibody collaboration on October 1, 2026, to co-develop and co-commercialize four new long-acting antibodies. Sanofi will pay Regeneron a $1.0 billion upfront payment, with up to $7.0 billion more in milestones, and the two companies will share global profits equally. Regeneron also expects a third-quarter 2026 acquired IPR&D charge of about $22 million, or $0.18 per diluted share, and agreed to dismiss a lawsuit against Sanofi.
Sanofi will pay Regeneron a $1.0 billion upfront payment under the Sixth Amendment dated October 1, 2026.
Regeneron is eligible for up to an additional $7.0 billion in development, regulatory, and commercial milestone payments.
Regeneron expects a third-quarter 2026 acquired IPR&D charge of about $22 million pre-tax, reducing GAAP and non-GAAP EPS by about $0.18 per diluted share.
Regeneron agreed to dismiss its lawsuit over Sanofi's obligations to provide information on Dupixent commercialization and audit rights.
Kairos Pharma said interim Phase 2 data showed a statistically significant difference in progression-free survival for patients treated with ENV-105 plus apalutamide compared with apalutamide alone. The company also modified the trial protocol to enroll patients earlier in disease progression, with completion targeted in or before the fourth quarter of 2027.
Median progression-free survival was 17.7 months with ENV-105 plus apalutamide versus 2 months with apalutamide alone (P=0.0008).
The modified protocol enrolls patients after a PSA increase following upfront androgen signaling inhibitor treatment, randomized to enzalutamide alone or with ENV-105.
Kairos Pharma targets completing the Phase 2 trial in or before the fourth quarter of 2027.
Beeline Holdings said preliminary third-quarter 2026 results show revenue at its second-highest quarterly level in company history and its highest since 2021, along with its highest margins ever. The company also expects a smaller net loss and a smaller adjusted EBITDA loss than in the prior quarter, plus a cash position at least 50% above the end of Q2 2026, and announced a pending Home Equity Investment product. The figures are preliminary and remain subject to quarter-end close and auditor review.
Q3 2026 revenue expected to be the second-highest quarterly revenue in company history and the highest since 2021
Q3 2026 net loss expected to be lower than the Q2 2026 net loss; adjusted EBITDA loss expected to be the lowest in 5 years
Cash at end of Q3 2026 expected to be at least 50% higher than at end of Q2 2026
Pending Home Equity Investment (HEI) product launch, which the company says is less tied to interest rates
RPM International reported record first-quarter fiscal 2027 net sales of $2.22 billion, up 4.8%, with diluted EPS of $2.01 and adjusted diluted EPS of $1.98, up 5.3%. The company now expects full-year adjusted EBITDA to grow in the mid-single-digit range, compared with its prior outlook of 5% to 10%, so shareholders face a lower expected profit growth rate despite the strong quarter.
Net sales were $2.22 billion, up 4.8%, with 3.1% organic growth; net income attributable to stockholders was $256.4 million.
Adjusted EBITDA reached a record $405.5 million, up 4.5%; Construction Products Group adjusted EBITDA fell 9.7%.
Full-year fiscal 2027 adjusted EBITDA outlook is mid-single-digit growth, versus the previous 5% to 10%; sales outlook is mid-single-digit, versus the previous 3% to 7%.
Investor day is scheduled for November 9, 2026, at the Stonhard facility in New Jersey.
Barnwell Industries agreed on October 5, 2026 to sell its Canadian oil and natural gas business to 2798913 Alberta Ltd. for a base price of C$9 million, made up of C$4 million in cash and a 5% gross overriding royalty valued at C$5 million. The sale requires approval from holders of a majority of Barnwell's common stock and must close by January 18, 2027, or the agreement can be terminated. The company's board recommends that shareholders vote in favor of the transaction.
Base purchase price of C$9,000,000, including C$4,000,000 in cash and a 5% royalty valued at C$5,000,000
Purchaser paid a C$1,000,000 deposit into escrow at signing, to be credited to the price at closing
Closing requires shareholder approval, and the outside date is January 18, 2027
A buyer affiliate may purchase the royalty for C$5,000,000 after closing, and royalty payments received beforehand do not reduce that price
HighPeak Energy agreed on October 6, 2026 to sell $450 million of convertible preferred stock to two Indonesian investors, with closing expected in the fourth quarter of 2026. The company also obtained an $800 million reserve-based credit facility from Citibank and Fifth Third Bank, which it says will let it repay its existing $1.17 billion term loan in full. The preferred carries a 6.0% cash dividend and a $9.50 conversion price, so it adds a dividend obligation and possible future share issuance for common shareholders.
Investors agreed to buy 450,000 shares of Series A 6.0% Perpetual Convertible Preferred Stock at a $1,000 stated value, for about $450 million in gross proceeds
Preferred convertible into common stock at an initial conversion price of $9.50 per share
New $800 million reserve-based credit facility with Citibank, N.A. and Fifth Third Bank, expected to fund repayment of the $1.17 billion term loan
Each investor may nominate one director; the investment is expected to close in the fourth quarter of 2026, subject to customary conditions
On October 5, 2026, AMC completed a $3.97 billion refinancing that included $2,000 million of 8.875% first lien notes due 2031, an $850 million first lien term loan due 2031, and a $1,120 million second lien term loan at a fixed 11.25% due 2033. The proceeds were used to tender for and redeem AMC's 7.500% Senior Secured Notes due 2029, redeem Muvico's $903.4 million notes due 2029, and repay existing term loans. The company says the deal extends most of its debt maturities and reduces its cost of capital, but the new debt carries higher fixed rates than some of the instruments it replaced, so the net effect for shareholders depends on how the company manages these obligations.
$2,000 million 8.875% first lien notes due October 15, 2031, with semi-annual interest payable April 15 and October 15
$850 million first lien term loans due October 5, 2031, and $1,120 million second lien term loans at a fixed 11.25% due October 5, 2033
Tender offer for AMC Secured Notes: $355,515,000 of the $359,964,500 outstanding (about 98.8%) was tendered, with remaining notes to be redeemed on or about February 15, 2027
Muvico's $903.4 million 2029 senior secured notes to be redeemed in full
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.